Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada

Reuters

08/22

<a href="https://laohu8.com/S/MRNA">Moderna</a> Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada

CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2561477983"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561477983\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561477983?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-22 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561477983","market":"fut","top_or_hot":-1,"title":"Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-22 21:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4501","symbol_name":"段永平概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDLbtYKdL:1","article_id":"2561477983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561477983","pubTimestamp":1755869156,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4501":"段永平概念","BK4551":"寇图资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念","MRNA":"Moderna, Inc.","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Moderna获得加拿大卫生部批准针对变种LP.8.1的更新COVID-19疫苗，并在加拿大生产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting Variant LP.8.1, with Production Set in Canada\n    \n\n        CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna Inc. has announced that Health Canada has approved its updated COVID-19 mRNA vaccine, Spikevax®, which targets the SARS-CoV-2 LP.8.1 variant. This authorization marks a significant milestone as it allows Moderna to supply Canadian communities with domestically-produced Spikevax doses for the first time. The vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries, with additional regulatory reviews underway globally. All pre-filled syringe doses for the Canadian market will be manufactured in Canada, with drug substance production in Laval, Quebec, and fill-finish operations in Cambridge, Ontario. Canadians are advised to consult provincial health authorities for the latest on vaccine eligibility and availability.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1064186) on August 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}